Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback